Page 3 - Michael Edel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Completion of Phase 1 testing demonstrates 91% sensitivity and 85% specificity Further optimisation studies are currently being performed and are expected to continue to improve results and match WHO standards Next steps are completion of regulatory approvals and moving the technology to market as soon as possible ZURICH, SWITZERLAND – EQS Newswire – 25 January 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) along with Regenacellx.sl, announces the completion of their Phase 1 study, for the group’s patent pending, nanoparticulate DNA aptamer conjugate and diagnostic testing technology...

Press release content from Accesswire. The AP news staff was not involved in its creation. Achiko concludes Phase 1 study of Project Gumnuts for Covid-19 testing January 25, 2021 GMT - Completion of Phase 1 testing demonstrates 91% sensitivity and 85% specificity- Further optimisation studies are currently being performed and are expected to continue to improve results and match WHO standards- Next steps are completion of regulatory approvals and moving the technology to market as soon as possibleZURICH / ACCESSWIRE / January 25, 2021 / Achiko AG (SWX:ACHI) (ISIN CH0522213468) along with Rege...